Market Access News | pharmaphorum

News

NICE backs Alnylam's Amvuttra for rare form of amyloidosis

Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available

News

Luye claims its first FDA approval, for bi-weekly schizophre...

China's Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks.

News

Female doctor with the stethoscope holding heart

NICE says statins should be used more widely in NHS

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

News

EU clears AstraZeneca's new-form severe asthma drug Tezspire

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.

News

EU clears Roche's flu drug Xofluza in very young children

With this year's influenza season off to an early start and showing signs of being particularly aggressive, the EU has extended the approved uses of Roche's antiviral Xofluza to include tre

News